DK0510167T3 - Hidtil ukendt fremgangsmåde til fremgangsmåde til krystallisation af organiske steroid forbindelser og de derved fremstillede forbindelser - Google Patents

Hidtil ukendt fremgangsmåde til fremgangsmåde til krystallisation af organiske steroid forbindelser og de derved fremstillede forbindelser

Info

Publication number
DK0510167T3
DK0510167T3 DK92900237.6T DK92900237T DK0510167T3 DK 0510167 T3 DK0510167 T3 DK 0510167T3 DK 92900237 T DK92900237 T DK 92900237T DK 0510167 T3 DK0510167 T3 DK 0510167T3
Authority
DK
Denmark
Prior art keywords
pct
compounds
crystallization
mixture
organic
Prior art date
Application number
DK92900237.6T
Other languages
English (en)
Inventor
Michel Lanquetin
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Application granted granted Critical
Publication of DK0510167T3 publication Critical patent/DK0510167T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK92900237.6T 1990-11-12 1991-11-12 Hidtil ukendt fremgangsmåde til fremgangsmåde til krystallisation af organiske steroid forbindelser og de derved fremstillede forbindelser DK0510167T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013981A FR2668945B1 (fr) 1990-11-12 1990-11-12 Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (1)

Publication Number Publication Date
DK0510167T3 true DK0510167T3 (da) 1996-01-02

Family

ID=9402062

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92900237.6T DK0510167T3 (da) 1990-11-12 1991-11-12 Hidtil ukendt fremgangsmåde til fremgangsmåde til krystallisation af organiske steroid forbindelser og de derved fremstillede forbindelser

Country Status (17)

Country Link
US (1) US5266712A (da)
EP (1) EP0510167B1 (da)
JP (1) JP3281954B2 (da)
KR (1) KR100196895B1 (da)
AT (1) ATE126806T1 (da)
BR (1) BR9106012A (da)
CA (1) CA2073760C (da)
DE (1) DE69112379T2 (da)
DK (1) DK0510167T3 (da)
ES (1) ES2079172T3 (da)
FI (1) FI111545B (da)
FR (1) FR2668945B1 (da)
GR (1) GR3018117T3 (da)
HU (1) HU212780B (da)
LV (1) LV11183B (da)
RU (1) RU2126013C1 (da)
WO (1) WO1992008730A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
DK1361881T3 (da) * 2000-12-14 2006-02-20 Ortho Mcneil Pharm Inc Steroide hormonprodukter og fremgangsmåder til fremstilling heraf
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
WO2005074942A1 (en) * 2004-02-04 2005-08-18 Retmed Pty Ltd Slow release steroid composition
RU2253453C1 (ru) * 2004-03-15 2005-06-10 Общество с ограниченной ответственностью "ЮНАЛ" Противовоспалительная и антиаллергическая композиция
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
EP1931682A2 (en) * 2006-08-03 2008-06-18 Teva Pharmaceutical Industries Ltd. Process for preparing clopidogrel bisulphate
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
MX393195B (es) * 2012-06-18 2025-03-24 Therapeuticsmd Inc Capsula de estradiol soluble para insercion por via vaginal
CN112871079B (zh) * 2021-01-27 2023-05-16 丽江映华生物药业有限公司 醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) * 1937-09-04 1944-10-31 Schering Corp Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) * 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3836628A (en) 1972-05-22 1974-09-17 Int Research & Dev Co Ltd Crystal growth modifier
DE2323812A1 (de) * 1973-05-11 1974-11-28 Jenapharm Veb Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
US4634694A (en) * 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4795747A (en) * 1985-12-23 1989-01-03 Latman Neal S 16-epiestriol to prevent, inhibit or reduce inflammation
US4956600A (en) * 1988-07-01 1990-09-11 Viteq Corporation High frequency current detector for a low frequency line

Also Published As

Publication number Publication date
JP3281954B2 (ja) 2002-05-13
HU212780B (en) 1996-11-28
DE69112379D1 (de) 1995-09-28
GR3018117T3 (en) 1996-02-29
RU2126013C1 (ru) 1999-02-10
EP0510167A1 (fr) 1992-10-28
FR2668945A1 (fr) 1992-05-15
US5266712A (en) 1993-11-30
LV11183B (en) 1996-10-20
KR927003617A (ko) 1992-12-18
CA2073760C (fr) 2003-09-23
JPH05503305A (ja) 1993-06-03
ES2079172T3 (es) 1996-01-01
KR100196895B1 (ko) 1999-06-15
HUT61319A (en) 1992-12-28
BR9106012A (pt) 1993-01-05
FR2668945B1 (fr) 1993-02-19
DE69112379T2 (de) 1996-03-28
ATE126806T1 (de) 1995-09-15
LV11183A (lv) 1996-04-20
HU9202608D0 (en) 1992-10-28
FI923188L (fi) 1992-07-10
CA2073760A1 (fr) 1992-05-13
FI111545B (fi) 2003-08-15
EP0510167B1 (fr) 1995-08-23
WO1992008730A1 (fr) 1992-05-29
FI923188A0 (fi) 1992-07-10

Similar Documents

Publication Publication Date Title
GR3018117T3 (en) Novel steroidal organic substance crystallization method and compounds thereby obtained.
HUP0001547A2 (hu) Az S-omeprazol új formája
CO5011099A1 (es) Formulaciones en polvo en estado cristalino estable
SK286488B6 (sk) Spôsob výroby polymorfnej formy I a II 17ß-(N-terc.butylkarbamoyl)-4-aza-5alfa-androst-1-en-3-onu
RU2001118035A (ru) Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы
DK162518B (da) Fremgangsmaade til fremstilling af en stabil modifikation af torasemid, samt et farmaceutisk praeparat indeholdende denne
DK210888A (da) Fremgangsmaade til fremstilling af en hoejresmeltende polymorf form af terfenadin
KR900013950A (ko) (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 화합물 및 약학적 담체를 함유한 약학적 조성물
JPS6471816A (en) Pharmacologically useful polymetamorphosis of buspirone
MY126071A (en) Crystalline form ii of cabergoline.
IT1165252B (it) Procedimento di purificazione dell'acido ursodesossicolico attraverso nuovi derivati
DK165322C (da) Derivater af 4,5-dihydrooxazolyl-2-oe(2-pyridyl)-methylthioaa-benzimidazoler eller -thienoimidazoler, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende saadanne derivater
CO4480032A1 (es) Cristales de glicosidos de espiroestanilo
Yershov et al. Preparation of gallium arsenide films on insulators by artificial epitaxy
JPS55144422A (en) Purification of cis-dichlorodiammineplatinum(2)
US2557655A (en) Estrone-cyclo-ethanolamine
Prits et al. Phase Equilibria in Pb--P--S (Se) Systems
MX168731B (es) Dicromato de sodio anhidro en escamas; procedimiento y aparato para su preparacion a escala industrial
SU1737036A1 (ru) Способ извлечени монокристаллов YB @ С @ О @ из затвердевшего раствора-расплава
JPH0354819A (ja) Ｓｏｉ基板の製造方法
WO2026014573A1 (ko) L-세린의 신규한 결정형 및 이의 제조 방법
WO2004087683A1 (en) Novel crystalline forms of valdecoxib
JPS549257A (en) Preparation of highly pure 1,8-dihydroanthraquinone
KR920003569A (ko) 란탄늄 알루미네이트 박막의 제조방법
Meikle Synthesis of 1, 2, 3, 4, 5-Tetrachlorobenzene-1-Cl36